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ARTICLE OPEN
Production, quality control, stability, and potency of cGMP-
produced Plasmodium falciparum RH5.1 protein vaccine
expressed in Drosophila S2 cells
Jing Jin1, Richard D. Tarrant2, Emma J. Bolam2, Philip Angell-Manning2, Max Soegaard3, David J. Pattinson1, Pawan Dulal1, Sarah E. Silk1,
Jennifer M. Marshall1, Rebecca A. Dabbs1, Fay L. Nugent1, Jordan R. Barrett1, Kathryn A. Hjerrild1, Lars Poulsen3, Thomas Jørgensen 3,
Tanja Brenner2, Ioana N. Baleanu2, Helena M. Parracho2, Abdessamad Tahiri-Alaoui2, Gary Whale2, Sarah Moyle2, Ruth O. Payne1,
Angela M. Minassian1, Matthew K. Higgins4, Frank J. Detmers5, Alison M. Lawrie1, Alexander D. Douglas1, Robert Smith2,
Willem A. de Jongh3, Eleanor Berrie2, Rebecca Ashﬁeld1 and Simon J. Draper 1
Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for
malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under
cGMP using the ExpreS2 platform (based on a Drosophila melanogaster S2 stable cell line system). Following development of a high-
producing monoclonal S2 cell line, a master cell bank was produced prior to the cGMP campaign. Culture supernatants were
processed using C-tag afﬁnity chromatography followed by size exclusion chromatography and virus-reduction ﬁltration. The
overall process yielded >400mg highly pure RH5.1 protein. QC testing showed the MCB and the RH5.1 product met all speciﬁed
acceptance criteria including those for sterility, purity, and identity. The RH5.1 vaccine product was stored at −80 °C and is stable for
over 18 months. Characterization of the protein following formulation in the adjuvant system AS01B showed that RH5.1 is stable in
the timeframe needed for clinical vaccine administration, and that there was no discernible impact on the liposomal formulation of
AS01B following addition of RH5.1. Subsequent immunization of mice conﬁrmed the RH5.1/AS01B vaccine was immunogenic and
could induce functional growth inhibitory antibodies against blood-stage P. falciparum in vitro. The RH5.1/AS01B was judged
suitable for use in humans and has since progressed to phase I/IIa clinical trial. Our data support the future use of the Drosophila S2
cell and C-tag platform technologies to enable cGMP-compliant biomanufacture of other novel and “difﬁcult-to-express”
recombinant protein-based vaccines.
npj Vaccines (2018)3:32 ; doi:10.1038/s41541-018-0071-7
INTRODUCTION
Malaria caused by the parasite Plasmodium falciparum continues
to exert a huge burden on global public health, with over 200
million clinical cases annually and approximately half a million
deaths.1 Central to ongoing efforts to develop highly effective
vaccines against malaria infection, disease, or transmission is the
production of recombinant proteins for use as subunit vaccines.2
These vaccines seek to induce antibodies that interfere with
critical steps during the parasite’s complex lifecycle—including
sporozoite invasion of the liver, merozoite invasion of the red
blood cell (RBC), sequestration of infected RBC, or sexual
replication and midgut traversal by the parasite within the
mosquito.3 Recombinant vaccine antigen may take numerous
forms, ranging from simple peptide to soluble monomeric protein
through to oligomeric scaffolds4,5 or larger virus-like particles
(VLPs).6–8
Typical delivery of these vaccines requires formulation of the
protein antigen with a deﬁned chemical adjuvant9,10 in order to
maximize quantitative antibody immunogenicity, while maintain-
ing acceptable levels of reactogenicity and aiming to avoid
detrimental impact of the adjuvant on the protein’s conforma-
tional integrity. Notable successful recombinant human vaccines
include hepatitis B virus surface antigen (HBsAg) and human
papillomavirus.
The blood-stage of malaria infection leads to the associated
morbidity and mortality through a variety of pathological
mechanisms.11 Vaccines targeting this stage thus aim to protect
against death and clinical disease, while also combating
transmission via reduction in blood-stage parasitemia. In this
regard, merozoite proteins involved in RBC invasion have
traditionally been targeted via the induction of growth inhibitory
antibodies,3 however historical candidate antigens have suffered
from substantial levels of polymorphism and redundancy, leading
to non-protective or strain-speciﬁc vaccine-induced antibody
responses.12,13 Recently, a number of more promising antigens
have been identiﬁed that are relatively highly conserved and yet
remain susceptible to neutralizing vaccine-induced antibodies.2
The most advanced of these candidates is the P. falciparum
reticulocyte-binding protein homolog 5 (PfRH5).14
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Vaccination of animals with PfRH5 induces antibodies that
inhibit all P. falciparum lines and ﬁeld isolates tested to date.15–18
PfRH5 is also essential,19,20 forming a non-redundant interaction
with basigin (CD147) on the RBC surface during invasion.21 The
high degree of PfRH5 sequence conservation is associated with
low-level immune pressure following years of natural malaria
exposure,15,22–24 coupled with functional constraints linked to
basigin binding and host RBC tropism.20,25–27 Notably, Aotus
monkeys were protected by PfRH5 vaccination against a stringent
heterologous strain blood-stage P. falciparum challenge.28 In this
study, anti-PfRH5 serum IgG antibody concentration and in vitro
growth inhibition activity (GIA) measured using puriﬁed IgG were
both associated with protective outcome in vivo.
Consequently, there has been strong impetus to progress
PfRH5-based vaccines into early-phase clinical testing. The ﬁrst
reported clinical trial utilized a recombinant adenovirus-poxvirus
vectored platform to deliver PfRH5 in healthy UK adults.24 The
vaccines were shown to be safe, and led to the induction of
PfRH5-speciﬁc antibodies, B-cell and T-cell responses, exceeding
the serum antibody responses observed in African adults
following years of natural malaria exposure. However, these
serum antibody responses still only reached peak median levels of
~9 μg/mL PfRH5-speciﬁc IgG, suggesting substantial room for
improvement in terms of quantitative vaccine immunogenicity.
Indeed, previous malaria vaccine candidates delivered as recom-
binant antigen formulated in strong adjuvant (such as Alhydrogel
+ CPG 7909 or GlaxoSmithKline’s (GSK) adjuvant system AS01B)
have achieved peak responses of ≥100 μg/mL antigen-speciﬁc
serum IgG in humans.29–31
Immunization of animals with full-length PfRH5 protein antigen
leads to the induction of neutralizing antibodies,15–18 in contrast
to the earliest vaccination studies that used PfRH5 fragments
made in Escherichia coli, which failed to induce functional
antibodies.19,32 In order to progress clinically, it has therefore
been critical to develop a protein expression and puriﬁcation
process that (i) allowed for production of full-length PfRH5 protein,
and (ii) was scalable and compliant with current good manufac-
turing practice (cGMP). In this regard, we reported the production
of soluble full-length PfRH5 protein using a cGMP-compliant
platform called ExpreS2, based on a Drosophila melanogaster
Schneider 2 (S2) stable cell line system.33,34 Full-length PfRH5
protein was expressed from stable S2 cell lines and secreted into
the supernatant from where it was puriﬁed using a newly available
afﬁnity puriﬁcation system that makes use of a C-terminal tag
known as “C-tag,” composed of the four amino acids (aa) glutamic
acid–proline–glutamic acid–alanine (E-P-E-A).35 This C-tag is
selectively captured on a resin coupled to a camelid single-chain
antibody speciﬁc for this short sequence36 that has now been
developed into a CaptureSelect™ afﬁnity resin by Thermo Fisher
Scientiﬁc.
Here we describe the production, quality control, stability, and
potency of a full-length PfRH5 soluble protein vaccine called
RH5.1, which we produced to cGMP using the ExpreS2 and C-tag
platform technologies at the University of Oxford’s Clinical
BioManufacturing Facility (CBF). Given the limited prior use of
Drosophila S2 cells and C-tag resin for cGMP vaccine production,
this biomanufacturing process necessitated the development of
new processes and consultation with the UK regulator—the
Medicines and Healthcare products Regulatory Agency (MHRA).
This work led to the successful production of >400mg RH5.1
protein vaccine, which has subsequently progressed to phase I/IIa
clinical testing in healthy adults in Oxford, UK formulated with
GSK’s adjuvant AS01B (Clinicaltrials.gov NCT02927145).
RESULTS
Generation of a monoclonal Drosophila S2 stable cell line
expressing the RH5.1 protein vaccine
We have previously reported the production of preclinical-grade
full-length PfRH5 protein vaccines using polyclonal Drosophila
S2 stable cell lines.33,35 For cGMP biomanufacture, we designed a
ﬁnal protein variant, termed “RH5.1” (Fig. 1a). The synthetic gene
was subcloned into the pExpreS2−1 plasmid allowing for zeocin
selection in transfected Drosophila S2 cells. Stable polyclonal cell
lines were initially established and evaluated by ELISA to conﬁrm
RH5.1 expression. These cell lines were then cloned by limiting
dilution to generate 124 RH5.1-producing clones. These were
expanded to shake ﬂasks and tested for RH5.1 protein yield by
ELISA, where a large variation was observed (Fig. 1b). The 37 best
expressing clones entered a stability evaluation scheme in order
to determine their stability with respect to growth, viability (data
not shown) and productivity (shown for two example clones in
Fig. 1c). Expression levels were stable over time for both clones
(maximum range 0.45–2.0 times the level measured on day 1). The
highest producing stable clone was identiﬁed as clone 38, with
Fig. 1 RH5.1 protein vaccine monoclonal stable S2 cell line generation. a Schematic of RH5.1 encoding from the N-terminus: a BiP insect
signal peptide (green) followed by PfRH5 (aa E26-Q526) (blue), followed by a C-terminal four amino acid C-tag (EPEA). The protein was based
on the P. falciparum 3D7 clone sequence, which has cysteine (C) at polymorphic position 203 (yellow circle). The other cysteine residues in
PfRH5 are indicated by small black boxes (C224, C317, C329, C345, and C351). Threonine (T) to alanine (A) substitutions to remove N-linked
glycan sequons are indicated by red asterisks. The predicted molecular weight (Mw) is 60.2 kDa. b A total of 124 single clones were selected
and expanded in shake ﬂasks. RH5.1 expression levels in the medium were assessed by quantitative ELISA. The distribution of expression
levels is shown from highest through to lowest. c A total of 37 clonal cell lines were assessed for stability with respect to growth, viability, and
productivity for up to 73 days. Example productivity data are shown for two clones (38 and 77) over a 39-day period. RH5.1 expression levels
were assessed at indicated time points by ELISA, and are normalized to the concentration of RH5.1 measured on day 1 (set as 1.0)
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productivity of ~100–150 mg/L by ELISA. Clone 38 cells were
expanded and frozen in aliquots to produce the RCB.
The RCB for clone 38 was subsequently transferred to the CBF,
University of Oxford, UK where one vial was thawed and used to
produce 175 vials of a MCB, called “OxS2-RH5.1c38 MCB1.” Testing
of the MCB conﬁrmed its identity and sterility, and that it was
negative for mycoplasma and spiroplasma. All other tests for
adventitious agents met speciﬁed acceptance criteria (Table 1).
Production and puriﬁcation of the RH5.1 vaccine clinical batch
Extensive PD studies and production of an engineering batch of
RH5.1 prior to cGMP manufacture had determined critical process
parameters for each step in the ﬁnal vaccine production process
(Fig. 2a). The engineering batch was produced using the same RCB
with identical process but at 1/10 the scale of the clinical batch.
Each process step was scaled down according to manufacturers’
recommendations to ensure critical process parameters were
consistent between the batches. In addition, a viral clearance
study was undertaken in order to establish the ability of two keys
steps in the cGMP biomanufacturing process, namely C-tag afﬁnity
chromatography and virus-reduction ﬁltration, to effectively
remove and/or inactivate (a) viruses, which are known to or could
contaminate the starting materials, or (b) novel and unpredictable
viruses. West Nile virus (WNV) and Porcine parvovirus (PPV) were
used as models for these potential contaminants; WNV was
selected as an example of an arbovirus (which can infect both
insect and mammalian cells) and PPV as an example of a non-
enveloped virus, which is highly resistant to chemical or physical
destruction (Table 2). As indicated in the Committee for
Proprietary Medicinal Products (CPMP) Note for Guidance on
Virus Validation Studies (CPMP/BWP/268/95) from the European
Medicines Agency, virus-reduction factors of ≥4 log10 are
indicative of a clear effect for each particular virus. For steps
where reduction factors of 1–3.9 log10 are reported, these steps
contribute signiﬁcantly to the overall removal and/or inactivation
of virus and were therefore included in determination of the
overall log10 reduction value. Overall, log10 reduction factors for
the two steps investigated during this study were in excess of 7.5
log10, indicating that the cGMP process as a whole is effective in
removing contaminating viruses.
cGMP production of the RH5.1 protein vaccine was thus
performed at 25-L scale using ten 5-L shake ﬂasks. Cell expansion
occurred over 17 days with 7 cell passages. The cells showed
≥99% viability at the time of collection, and a density of 4.2 × 107/
mL. Subsequent downstream puriﬁcation yielded 444mg of RH5.1
protein (overall process yield of 17.7 mg/L). Approximately 94mg
of the ﬁnal RH5.1 bulk drug product was ﬁlled into 500 vials as the
clinical batch and stored at −80 °C. Test vials were subsequently
thawed for analysis by SDS-PAGE. This conﬁrmed a single main
band at the expected size of 60.2 kDa, which appeared identical to
the comparator engineering batch (Fig. 2b), with identity
conﬁrmed by western blot (Fig. 2c). Analysis by HPLC-SEC showed
no detectable aggregation and purity >95% (Fig. 2d). The product
therefore proceeded to further QC testing.
QC testing of the RH5.1 vaccine clinical batch
Testing of the RH5.1 clinical batch conﬁrmed its sterility, and that
it was negative for mycoplasma and spiroplasma. All other tests
for adventitious agents, endotoxin, protein concentration, appear-
ance, pH, osmolality, residual host-cell DNA, and residual host-cell
protein (tested by western blot) met speciﬁed acceptance criteria
(Table 3). The product was also tested for residual anti-C-tag
camelid single-chain antibody that could have leached from the
afﬁnity column—this test was passed with the product showing
<2 ng/mL. In light of the results for the MCB testing (Table 1), the
RH5.1 vaccine was also tested for copia retrotransposon gag
protein by western blot, with results showing this to be negative.
Table 1. Characterization and testing of the OxS2-RH5.1c38 MCB
Test Speciﬁcation Result
Host-cell identity by random ampliﬁed polymorphic DNA (RAPD) assay Positive Positive
Sterility Pass Pass
Mycoplasma Negative Negative
Spiroplasma Negative Negative
Fluorescent product-enhanced reverse transcriptase (F-PERT) assay Negative Positivea
Electron microscopy examination of 200 median cell proﬁles Negative Positivea
Real-time PCR detection of porcine/bovine cirovirus (PCV) Negative Negative
Enhanced detection of a range of adventitious bovine and porcine viruses by nine CFR
regulations using swine testis, bovine turbinate, and vero cells
Negative Negative
Real-time PCR detection of ﬂock house virus Negative Negative
Viral contamination in vitro cytotoxicity Report result Test item was not cytotoxic to any of
the cell lines tested
Viral contamination in vitro: 28-day assay for detection of viral contaminants using four
detector cell lines (MRC5, Vero, BHK, and C6/36)
Negative Negative
Viral contamination in vivo: detection of toxicity of test article breakthrough (post
neutralization) in suckling mice, adult mice, and guinea pigs
Report result Test item free from toxic agents
Viral contamination in vivo: test for presence of inapparent viruses using suckling mice,
adult mice, and guinea pigs
No viruses detected No viruses detected
aHEK293 co-cultivation assay with F-PERT end point Pass Negative (pass)
Tests are listed with pre-deﬁned speciﬁcation and test results
aIt was expected that the F-PERT assay for reverse transcriptase activity and TEM analysis of the MCB would be positive due to the presence of copia
retrotransposons in Drosophila S2 cells. These cells have been observed to produce intracellular VLPs, but these have only ever been found to contain copia-
derived protein and nucleic acid.67 For this reason, the HEK293 co-cultivation assay with F-PERT end point was initiated to test for retrovirus infectivity using
mammalian cells as per guidelines in the European Pharmacopoeia
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The ability of RH5.1 protein to bind to recombinant basigin was
subsequently analyzed by SPR, which measured an afﬁnity of
1.2 μM, consistent with previously reported measurements of KD
= 1–2 μM21,28,33,35 (Fig. 3a). The ability of RH5.1 protein to be
recognized by a panel of eight previously characterized mouse
mAbs37 was also assessed by ELISA (Fig. 3b), conﬁrming the
presence of each epitope in the protein. Potency of the RH5.1
vaccine clinical batch was ﬁnally determined by a sandwich ELISA-
based assay, using RH5.1 capture by the mouse mAb 4BA7 (which
binds a linear peptide within the internal disordered loop of
PfRH5), followed by detection with a non-competing, conforma-
tion-sensitive, neutralizing mAb 2AC7 (chimerized to have human
IgG1 Fc in place of the parental mouse Fc). These data conﬁrmed
the clinical RH5.1 batch showed a relative potency that matched
the 100% standard used in the assay (Fig. 3c).
Stability of the RH5.1 vaccine clinical batch
Stability studies were conducted on both the engineering batch
and the ﬁnal vialled product. The engineering batch was
formulated in the same buffer as the cGMP-produced RH5.1 and
stored at the planned storage temperature of −80 °C (range −70
to −85 °C), as well as at +4 °C (range 2–8 °C) to get accelerated
insight of long-term product stability. The engineering batch was
tested for protein degradation by SDS-PAGE (Fig. 4a), protein
aggregation by analytical SEC (Fig. 4b), and identity and activity by
a dot blot against the 2AC7 mAb (data not shown). All three test
methods showed no detectable change in the RH5.1 protein over
19 months stored at −80 °C in comparison to the starting material
(from the ﬁrst assay time point). Similar results were obtained with
Fig. 2 Analysis of the puriﬁed ﬁnal RH5.1 drug product. a Overview of RH5.1 protein vaccine cGMP production process. b SDS-PAGE and c
western blot (under reducing conditions) of the ﬁnal RH5.1 drug product produced to cGMP (G) run alongside the comparator engineering
batch (E). The western blot used the anti-PfRH5 4BA7 mouse mAb. Within each panel, the gels derive from the same experiment and were
processed in parallel. d HPLC-SEC analysis of the ﬁnal RH5.1 drug product to assess aggregation. M molecular weight markers
Table 2. Viral clearance study
C-tag afﬁnity chromatography Run 1 Run 2
WNV 2.70 ± 0.43 log10 2.70 ± 0.41 log10
PPV 2.44 ± 0.56 log10 2.00 ± 0.38 log10
Virus-reduction ﬁltration Run 1 Run 2
WNV ≥5.00 ± 0.25 log10 ≥5.17 ± 0.34 log10
PPV ≥5.77 ± 0.36 log10 ≥5.69 ± 0.38 log10
Overall reduction factors
WNV ≥7.70 ± 0.50 log10
PPV ≥7.69 ± 0.54 log10
Starting materials were spiked with the selected viruses and samples
collected following the C-tag afﬁnity chromatography or virus-reduction
ﬁltration process steps. Virus titer of each sample was determined by a 50%
tissue culture infectious dose (TCID50) infectivity assay and the resultant
virus log10 reduction factors are reported
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the 14-day study conducted at 4 °C. SDS-PAGE analysis showed no
additional lower molecular weight bands compared with the day
1 starting material, although a band similar in size to the natural
~45 kDa cleavage product of PfRH519,38 became more pro-
nounced by day 14 (Fig. 4c). Analytical SEC showed no protein
aggregation, and a small shoulder by day 10–14 (in agreement
with the appearance of some smaller product in the SDS-PAGE)
(Fig. 4d). The potency sandwich ELISA (conducted on samples
from days 8, 10, and 14) showed a relative potency that matched
the 100% standard used in the assay (data not shown).
The clinical vaccine batch of RH5.1 is stored at −80 °C at the
CBF, University of Oxford. Stability testing of the vialled product
stored at −80 °C, as well as using an accelerated protocol at −20 °
C, remains ongoing. At each time point, the product is tested for
appearance (particles, color); pH; protein concentration; degrada-
tion by SDS-PAGE; identity by western blot; and potency by
sandwich ELISA. At the time of writing, the product has been
shown to be stable for at least 18 months, with no apparent
changes in comparison to the starting material (from the ﬁrst
assay time point) (data not shown). Overall, these data suggest the
cGMP-produced RH5.1 protein is stable and suitable for early-
phase clinical testing.
Characterization of the RH5.1/AS01B vaccine formulation
The vaccine product was subsequently assessed following
formulation of RH5.1 protein (cGMP product) in the clinical
adjuvant (ﬁnal concentration 100 μg/mL RH5.1 in AS01B). The pH
of the formulation was assessed immediately after mixing and was
determined to be 6.39. Stability of the RH5.1 protein was also
assessed by SDS-PAGE at various time points after formulation in
AS01B. These data showed no signiﬁcant change in the proﬁle of
RH5.1 immediately or after 1 and 4 h post mixing (Fig. 5, lanes
1–3). The ﬁrst clinical trial of RH5.1/AS01B also includes a 2 μg dose
lead-in group, necessitating a 1:5 dilution of the RH5.1 cGMP
product in the clinic using a mixing vial. This procedure was
assessed here using the clinical SOP, in order to assess for
potential loss of RH5.1 protein due to non-speciﬁc adsorption to
the mixing vial. Analysis by SDS-PAGE showed no signiﬁcant loss
of RH5.1 following this procedure (Fig. 5, lanes 4–6).
Finally, we tested for changes in AS01B particle size following
addition of RH5.1. Analysis of the size distribution by scattered
intensity for AS01B alone, AS01B+ RH5.1 immediately post mixing,
and AS01B+ RH5.1 stored for 1 h (to mimic bedside vaccine
administration) showed that the size of liposomes was not
changed post mixing, with median size of ~107 nm. As the
concentration of RH5.1 is low compared to AS01B, no separate
Table 3. Characterization of the RH5.1 vaccine clinical batch
Test Material Speciﬁcation Result
Sterility test Vialled
product
Pass Pass
Mycoplasma Bulk harvest
lot
Negative Negative
Spiroplasma Bulk harvest
lot
Negative Negative
Viral contamination in vitro: 28-day assay for detection of viral
contaminants using three detector cell lines (MRC5, Vero, and
C6/36)
Bulk harvest
lot
Negative Negative
Viral contamination in vivo: test for presence of inapparent
viruses using suckling mice, adult mice, and guinea pigs
Bulk harvest
lot
Negative Negative
Abnormal toxicity test Vialled
product
Pass Pass
Endotoxin Vialled
product
≤1400 EU/mL 0.482 EU/mL
Protein concentration Vialled
product
≥0.15mg/mL
≤1.0 mg/mL
0.174mg/mL
Appearance Vialled
product
Clear, colorless solution essentially free
of visible particles
Pass
pH Vialled
product
Formulation buffer ± 1.0 pH unit pH 7.14
Osmolality Vialled
product
200–600mOsMol/kg 319mOsMol/kg
Residual host-cell DNA Bulk product ≤10 ng per dose <180.0 pg/mL
Residual host-cell protein by western blot Bulk product Report result Negative
Residual C-tag ligand Bulk product ≤1 µg/mLa <2 ng/mL
Copia gag western blot Bulk product For information only Negative for copia protein
at ~31 kDa
Identity by western blot Vialled
product
Positive for RH5.1 Positive for RH5.1
Purity by SDS-PAGE Vialled
product
RH5.1 bands >90% of total bands
detected
>95%
HPLC-SEC Vialled
product
For information only Pass
Tests are listed with pre-deﬁned speciﬁcation, the cGMP production material used for testing, and the test result. N-terminal protein sequencing was not done
and was not required by the UK regulator (MHRA) for the RH5.1 vaccine to proceed to phase Ia clinical trial
aThis speciﬁcation was set to equate to <0.67% total protein
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peak for RH5.1 was observed in the mixture. AS01B was also
monodisperse (with no detectable aggregation) shown by a mean
polydispersity index <0.3 in all three conditions tested. Testing of
the RH5.1 protein alone did not yield reliable data due to the low
concentration of the vaccine product and small protein size (data
not shown). Overall, these data conﬁrmed that RH5.1 protein
appeared stable in AS01B adjuvant in the timeframe needed for
clinical vaccine administration, and there was no discernible
impact on the liposomal formulation of AS01B following addition
of RH5.1.
Immunogenicity of RH5.1 formulated with AS01B
Immunogenicity of RH5.1/AS01B was assessed following i.m.
immunization of BALB/c mice using protein from the RH5.1
engineering batch or the cGMP-produced RH5.1 clinical vaccine
both formulated in AS01B. An extra adjuvant alone group was
included as a negative control. Two weeks after the third and ﬁnal
immunization, spleens and sera were collected. An ex vivo IFN-γ
ELISpot assay using splenocytes re-stimulated with recombinant
RH5.1 protein or a pool of three peptides containing known H-2d
T-cell epitopes within PfRH5 showed similar cellular immunogeni-
city of both proteins with no signiﬁcant difference as assessed by
Mann–Whitney test (Fig. 6a). Similarly, the ELISA-detecting serum
IgG responses against RH5.1, showed no signiﬁcant difference
between the two proteins as assessed by Mann–Whitney test.
Finally, the IgG was puriﬁed from pooled sera and tested in a
functional assay of GIA against 3D7 clone P. falciparum parasites.
GIA was plotted against the RH5.1 responses measured by ELISA in
the puriﬁed IgG used in the assay (Fig. 6c). There was no
detectable GIA in the AS01B only-immunized group (data not
shown). These data showed that GIA was associated with anti-
PfRH5 IgG as measured by ELISA, with a typical sigmoidal
relationship, as observed in numerous studies with other
antigens39,40 and both preclinical and clinical studies with
PfRH5-based vaccines.24,33,35 The EC50s were also very similar for
both the RH5.1 engineering batch and the clinical vaccine,
conﬁrming they elicit a very similar quality of antibody response.
Overall, these data conﬁrmed the immunogenicity of the RH5.1/
AS01B clinical vaccine and demonstrated that it could induce
functional growth inhibitory antibodies.
DISCUSSION
Biomanufacture in accordance with cGMP is a critical step in the
translation of any new vaccine into clinical testing. The ﬁeld of
malaria vaccines has historically seen many candidate antigens
from all lifecycle stages produced for clinical trial as recombinant
proteins in bacterial- and yeast-based expression platforms
including E. coli,41–47 Lactococcus lactis,48 Saccharomyces cerevi-
siae49,50 and Pichia pastoris.51–54 However, generation of full-
length PfRH5 protein proved particularly problematic in these
heterologous expression platforms. Consequently, viral-vectored
immunization led to the ﬁrst promising results in animal models,15
whereby antigen is expressed in situ from virally infected muscle
cells.55 Subsequently, a numer of groups reported production of
preclinical-grade full-length PfRH5 protein using mammalian
HEK293 cells,21,56 E. coli,18,57 baculovirus-infected insect cells58,59
and a wheatgerm cell-free expression platform,60 but not yeast-
based systems. However, each approach faced different chal-
lenges for onward clinical development—these included the need
for clinically incompatible C-terminal tags such as rat CD4 domains
3 and 4; production of insoluble protein within inclusion bodies;
extremely low yield; or lack of a scalable cGMP-compliant process.
Our subsequent demonstration that the ExpreS2 D. melanogaster
Fig. 3 Characterization of RH5.1 clinical vaccine. a SPR analysis of the interaction of RH5.1 protein with basigin. b Anti-RH5.1 ELISA using a
panel of eight PfRH5-speciﬁc mouse mAbs. Each sample was tested in triplicate. Bars show the mean plus range. c Potency ELISA using RH5.1
test sample versus RH5.1 protein standards (100, 50, and 20% concentration). Each point is the mean of triplicate readings. pAb mouse anti-
PfRH5 polyclonal antibody serum control
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S2 stable cell line system,34 coupled with C-tag afﬁnity puriﬁca-
tion,35 was suitable for production of soluble full-length PfRH5
protein has now enabled the cGMP biomanufacture of a batch of
RH5.1 clinical vaccine.
Prior to the cGMP biomanufacture campaign, a stable mono-
clonal RCB was generated by ExpreS2ion Biotechnologies under
GLP conditions. Generation of a monoclonal cell line allowed for
identiﬁcation of a stable and high-producing clone, with RH5.1
levels >100mg/L observed in 4% of the clones tested. This
represented a 3–20-fold improvement over the expression levels
observed from previously reported polyclonal S2 cell lines
expressing PfRH5 protein variants,33 and allowed for viable
progression to cGMP biomanufacture. Similar experiences in
terms of isolating stable high-expressing monoclonal cell lines
have been reported for a VAR2CSA-based P. falciparum vaccine for
placental malaria produced in the same S2 cell system.61 Cell line
expression level likely reﬂects a mixture of multiple transgene
insertions following plasmid transfection as well as stochastic
insertion loci within the S2 cell genome. Parameters that
otherwise affect transgene expression from S2 cells remain poorly
deﬁned.
The monoclonal RCB was subsequently expanded under cGMP
clean room conditions to produce the MCB. Extensive PD studies
were undertaken to deﬁne the ﬁnal upstream and downstream
production process, alongside a viral clearance study to satisfy the
regulatory requirement to demonstrate effective removal of
potentially contaminating viruses. During these studies, we noted
a consistent 100 kDa contaminant following C-tag column elution,
which we identiﬁed by mass spectrometry as the Drosophila
midline fasciclin protein.62 This protein does not have the C-
terminal amino acids EPEA, suggesting a non-speciﬁc interaction
with RH5.1 or the C-tag resin. This contaminant was different to a
38 kDa contaminant commonly observed when we previously
puriﬁed PfRH5 proteins from polyclonal S2 cell lines,33 suggesting
major contaminants can differ between clonal cell lines. However,
this host-cell contaminant was effectively removed by the SEC
polishing step, and the overall process ultimately yielded >400mg
highly pure RH5.1 protein from a 25-L batch produced in shake
ﬂasks. Ninety-four milligrams were subsequently ﬁlled into vials to
produce the clinical vaccine lot, which on undergoing QC testing
met all speciﬁed acceptance criteria.
This cGMP biomanufacture campaign also necessitated use of
the C-tag resin, which is now commercially available. Notably,
multiple different single-chain antibody-based afﬁnity resins are
available, known collectively as CaptureSelect™ technology, and
the ﬁrst product puriﬁed in this manner (an adeno-associated
virus gene therapy product called alipogene tiparvovec (Glybera®)
for lipoprotein lipase deﬁciency) has been licensed in Europe.63,64
Notably, use of the C-tag minimizes extra sequence in this vaccine
to just four amino acids (excluding the BiP signal peptide that is
Fig. 4 Stability testing of RH5.1 protein. RH5.1 protein vaccine was assessed for stability over time. The engineering batch was tested for a
protein degradation by SDS-PAGE and b aggregation by analytical SEC following storage at −80 °C. Results are shown at the 0, 1, 2, 3, 6, 9, 12,
and 19-month time points. In b, each colored line shows a different time point. The engineering batch was also tested for c protein
degradation by SDS-PAGE and d aggregation by analytical SEC following storage at 4 °C as part of an accelerated stability study. Results are
shown at the 1, 2, 4, 8, 10, and 14-day (D) time points. Within a and c, the gels for each time point derive from different experiments, but are
shown aligned here for ease of comparison. m molecular weight markers
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cleaved from the protein during secretion from the S2 cells). Other
malaria vaccine candidates have included much larger tags (for
example two His6 tags) plus extra extraneous sequences (such as
linkers or cloning sites). In some cases, these have totaled up to 29
non-pathogen amino acids fused to the desired antigen.41–43
These vaccines have been approved by natioanl regulators,
including those in Europe and the US FDA, for clinical trials
ranging from phase Ia through to phase IIb efﬁcacy studies in
African children with no apparent safety concerns.29,65,66
Testing of the monoclonal MCB showed that it was positive for
reverse transcriptase activity with visible intracellular VLPs by TEM
—this was expected due to the presence of copia retrotranspo-
sons in Drosophila S2 cells, an observation ﬁrst made in 1972.67 D.
melanogaster copia is in the Hemivirus genus of the family
Pseudoviridae, and is a retrotransposon rather than a virus. The
Pseudoviridae family of retrotransposons are present in inverte-
brates and fungi (notably including the Ty elements present in
yeast such as Saccharomyces). There is no evidence that copia
VLPs are transmissible to mammalian cells, as conﬁrmed by a
subsequent HEK293 co-cultivation assay for retrovirus infectivity
as per guidelines in the European Pharmacopoeia. We therefore
regarded copia VLPs as a form of host-cell protein not associated
with any particular risks to human health. Moreover, it was highly
likely that minimal crossover would occur from nuclear-located
copia VLPs into the bulk harvest of the S2 cell supernatant, and
even then a signiﬁcant fold-reduction in copia VLP burden would
occur during the downstream puriﬁcation process as demon-
strated by the viral clearance study. The ﬁnal clinical batch of
Fig. 5 Characterization of the RH5.1/AS01B vaccine formulation.
Stability of the RH5.1 protein was assessed by SDS-PAGE at various
time points after formulation in AS01B. Lanes 1–3= immediate
testing or after 1 and 4 h post mixing, respectively. Samples were
also run on the same gel following testing of RH5.1 dilution using a
mixing vial as required for clinical vaccine administration. Lane 4=
RH5.1 diluted 1:5 with 0.9% saline in a clinical mixing vial. Lane 5=
RH5.1 undiluted standard, and lane 6= RH5.1 1:5 diluted standard.
The gel in this ﬁgure derives from a single experiment with all
samples processed in parallel
Fig. 6 Immunological analysis of RH5.1/AS01B in mice. a BALB/c mice (n= 6 per group) were immunized with 2 µg RH5.1/AS01B using the
cGMP-produced clinical vaccine batch (GMP) or the engineering batch of RH5.1 (Eng), or AS01B alone. Two weeks after the last immunization,
spleens were collected and T-cell responses were measured from spleen samples by ex vivo IFN-γ ELISpot following re-stimulation with RH5
peptides or RH5.1 protein. Median and individual data points are shown. b Serum IgG responses were measured by ELISA against RH5.1 using
pooled serum samples taken 4 weeks after the ﬁrst or second immunization using the cGMP-produced or engineering batches of RH5.1 (1-E,
1-G, 2-E, 2-G, respectively). Responses were measured in all mice 2 weeks after the third and ﬁnal immunization (3-G, 3-E). There was no
detectable IgG (N.D.) in any mouse following three immunizations with AS01B alone (3-A). Individual and median responses are shown. c
Functional GIA of puriﬁed IgG was assessed against 3D7 clone P. falciparum parasites. GIA is plotted against RH5.1 responses measured by
ELISA in the puriﬁed IgG samples used for the assay, in order to assess quality of the vaccine-induced antibody response. The dashed line
indicates 50% GIA. Non-linear least squares regression line is shown; r2= 0.99, n= 16
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RH5.1 vaccine was also speciﬁcally tested for copia retrotranspo-
son gag protein by western blot with results showing this to be
negative, alongside testing for residual host-cell protein that met
speciﬁed acceptance criteria.
Analysis of the RH5.1 clinical vaccine showed that it binds
basigin with the expected afﬁnity of 1–2 μM21,28,33,35 and that it is
recognized by a panel of eight previously characterized mouse
mAbs, many of which bind conformational epitopes.37,68 Stability
testing of the RH5.1 clinical batch also conﬁrmed the protein is
stable at −80 °C and suitable for early-phase clinical testing.
Notably, the ~45 kDa degradation product seen in the accelerated
+4 °C stability study is comparable to the natural N-terminal
cleavage product of PfRH5 found in parasite culture super-
natants,19,38 and similar recombinant truncated proteins of PfRH5
also show strong immunogenicity and induction of growth
inhibitory antibodies.68,69 We ﬁnally characterized RH5.1 following
formulation with AS01B adjuvant from GSK. These data showed
that the protein was stable in the timeframe vaccine will be
administered in the clinic, and that there was no discernible
impact on the liposomal formulation of the adjuvant. Subsequent
immunization of BALB/c mice conﬁrmed that the cellular and
humoral immunogenicity of the RH5.1 clinical batch was identical
to that observed with engineering batch material produced in
advance of the cGMP campaign. These vaccines elicited IgG that
showed the same functional GIA against P. falciparum blood-stage
parasites in vitro, in line with previous preclinical studies with
PfRH5-based vaccines.33,35
The RH5.1/AS01B vaccine has subsequently progressed through
a preclinical toxicology study and was approved by the UK MHRA
regulator for a phase I/IIa clinical trial in over 60 healthy adults in
Oxford, UK, (Clinicaltrials.gov NCT02927145) using doses of 2, 10,
and 50 μg. This trial will provide the ﬁrst data on the safety,
immunogenicity and efﬁcacy of this vaccine formulation in
humans (Minassian et al., in preparation). To date only a limited
number of products produced to cGMP in Drosophila S2 cells have
entered clinical testing—these include candidate vaccines for
WNV and dengue virus70,71 as well as the VAR2CSA-based vaccine
for malaria of pregnancy.61 Our data here further demonstrate the
utility of the Drosophila S2 cell platform for cGMP-compliant
biomanufacture and, alongside use of the C-tag puriﬁcation
technology, provide an alternative route for clinical translation of
other “difﬁcult-to-express” recombinant protein-based vaccines.
MATERIALS AND METHODS
Design and cloning of the RH5.1 protein vaccine
The design of the PfRH5 coding sequence within the RH5.1 protein vaccine
has been described elsewhere, where it was reported as variant version
2.0.33 In brief, the protein encodes the full-length PfRH5 antigen (aa E26-
Q526) based on the sequence of the 3D7 clone P. falciparum parasite, and
all four putative N-linked glycosylation sequons (N-X-S/T) were mutated
Thr to Ala—as performed for a previous PfRH5 protein vaccine produced in
mammalian HEK293 cells and tested in rabbits17,33 and Aotus monkeys.28
The synthetic gene for RH5.1 was codon-optimized for expression in D.
melanogaster and produced as a TSE-free product (GeneArt, Thermo Fisher
Scientiﬁc). The gene also contained a Kozak sequence (GCC ACC) at the 5′
end, an N-terminal 18-aa Ig heavy chain binding protein (BiP) insect signal
peptide (MKLCILLAVVAFVGLSLG) and a C-terminal four amino acid (EPEA)
C-tag.35 This gene insert was subcloned by GeneArt into the pExpreS2−1
plasmid allowing for zeocin selection33 (ExpreS2ion Biotechnologies,
Denmark) and veriﬁed by sequencing.
Generation of the monoclonal Drosophila S2 stable cell line
research cell bank
The Drosophila S2 cell line parental cell bank was established under Good
Laboratory Practice (GLP) conditions by ExpreS2ion Biotechnologies,
Denmark. A vial of the parental Drosophila S2 cell bank was resuscitated
in EX-CELL 420 media (Sigma-Aldrich, UK) with 10% TSE-free certiﬁed fetal
bovine serum (FBS) (provided by the CBF, University of Oxford) and
expanded in shake ﬂasks. Cells were transfected using ExpreS2 Insect-TRx5
reagent with the pExpreS2-1 plasmid encoding RH5.1 and cloned by
limiting dilution. TSE-free certiﬁed FBS was present during the resuscita-
tion, selection, and cloning process, but was removed by centrifugation
during scale-up to shake ﬂasks and replaced with serum-free medium, and
no further FBS was used during the establishment or freezing of the
Research Cell Bank (RCB). Stable polyclonal cell lines were selected by
adding zeocin to the cells 24 h post transfection. The established
polyclonal cell lines were evaluated by an anti-PfRH5 protein quantiﬁcation
ELISA (described in detail elsewhere33), and then diluted and seeded in 96-
well plates and incubated. Clones from approved 96-well plates (plates
containing less than one clone per three wells and visually conﬁrmed to be
single clones) were picked and transferred for further evaluation in 12-well
plates and tissue culture ﬂasks. A total of 124 RH5.1-producing clones were
expanded to shake ﬂasks and tested for protein expression by anti-PfRH5
protein quantiﬁcation ELISA. The best expressing clones were further
evaluated for their stability with respect to growth, viability, and
productivity for up to 73 days (48 generations).
The highest producing stable clone was identiﬁed as clone 38. An
ampoule of cells was frozen in CryoStor CS10 cryopreservation medium
(Sigma-Aldrich, UK) shortly after establishment of clone 38 and resusci-
tated after the stability study. The cell line was resuscitated in serum-free
and animal component-free EX-CELL 420 medium, and then expanded in
ESF-AF serum-free and animal component-free medium (Expression
Systems, USA) in shake ﬂasks until a RCB of 30 vials containing 2.5 × 108
cells per vial could be established. The cells were resuspended in Cryostor
CS10 cryopreservation medium in 1mL aliquots after centrifugation and
stored at −80 °C, before transfer to −150 °C the following day.
Generation and testing of the monoclonal Drosophila S2 stable cell
line master cell bank
A single vial of the RCB clone 38 starting material was thawed for Master
Cell Bank (MCB) generation in the cGMP clean room at the CBF, University
of Oxford. The cells were expanded in shake ﬂasks (25 °C, 130 r.p.m., and
using ESF-AF serum-free and animal component-free medium) and
maintained in the logarithmic phase of growth for 8 days until there were
sufﬁcient cells to lay down the MCB. Cells were frozen (1.5 × 108 cells per
vial) and stored at −80 °C and then transferred to liquid nitrogen vapor-
phase storage. The MCB was named OxS2-RH5.1c38. All assays for testing
of the MCB were performed by a contract research organization (CRO), SGS
Vitrology, according to their standard operating procedures (SOP).
cGMP production of recombinant RH5.1 ﬁnal drug product
A vial of the MCB was expanded in culture to express the recombinant
RH5.1 protein in the supernatant. The cells were scaled up from 20mL to
25L (10 × 5-L shake ﬂasks) over 17 days, while being maintained at 25 °C,
130 r.p.m. using ESF-AF serum-free and animal component-free medium
with 2% production boost additive (PBA) (Expression Systems, USA) and
0.025% anti-foam (FoamAway, Thermo Fisher Scientiﬁc, UK) added at the
last passage. The collected cell culture supernatant was then clariﬁed by
centrifugation (4000×g, 20 min, 20 °C), followed by 0.5/0.2 μm ﬁltration
(Opticap Express SHC, Merck Millipore, UK) for bioburden and aggregates
reduction. Thereafter, the material was concentrated by a tangential ﬂow
ﬁltration (TFF) system, ﬁtted with Pellicon 3 Ultracel 10 kDa membrane
(Merck Millipore, UK), in order to reduce the process volume for the
subsequent steps. Design of single-use TFF assemblies was carried out with
assistance from Merck Millipore, UK. Downstream process included a
puriﬁcation stack of a C-tag afﬁnity chromatography35 and a polishing size
exclusion chromatography (SEC), followed by a virus-reduction ﬁltration, all
performed on an ÄKTA Pilot system (GE Healthcare, UK). Suitable column
sizes and operating conditions were determined during process develop-
ment (PD). The ability to remove viral contaminants by the C-tag afﬁnity
chromatography and the virus-reduction ﬁltration steps was also demon-
strated in a viral clearance study, performed by a CRO (BioReliance)
according to their SOPs. C-tag afﬁnity resin (Thermo Fisher Scientiﬁc, UK)
and SepFast GF-HS-L SEC resin (BioToolomics, UK) were packed into single-
use columns, 50/30 (60 mL) and 50/1000 (2 L) respectively, by BioToo-
lomics. Both columns were sanitized and bioburden tested after packing
and before use. Concentrated culture supernatant was applied onto the C-
tag afﬁnity column. After washing, elution took place with 2 M MgCl2 and
eluted fractions were pooled and stored at −80 °C. On the following day,
C-tag column eluate was thawed and applied to the GF-HS-L SEC column,
previously equilibrated with formulation buffer (20 mM Tris, 150 mM NaCl,
Production, quality control, stability, and potency of cGMP
J Jin et al.
9
Published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2018)  32 
pH 7.4 in water-for-injection). Fractions corresponding to the product peak,
now in formulation buffer, were pooled, and 0.22 μm ﬁltered for bioburden
and aggregate reduction. The bulk puriﬁed lot was then ﬁltered through a
Viresolve Pro Modus 1.1 virus-reduction ﬁlter (Merck Millipore, UK), used
with a pre-ﬁlter for optimal loading capacity, to generate the drug
substance. The drug substance was then sterile ﬁltered to generate the
ﬁnal bulk drug product. This was aseptically ﬁlled into glass vials to
generate the ﬁnal RH5.1 drug product, presented as a solution for
injection. Each vial contained at least 165 μg in 0.95 mL formulation buffer.
Recombinant RH5.1 clinical batch testing
The tests undertaken in Table 3 were performed by CROs (SGS Vitrology or
RSSL Pharma) or by the CBF, University of Oxford according to their
standard protocols and in accordance with the European Pharmacopeia. In
brief, for sterility the test sample was aseptically transferred to soybean-
casein digest medium and ﬂuid thioglycollate medium. The broths were
inspected for evidence of bacterial and fungal growth. The sterility assay
was also qualiﬁed to ensure that the samples did not contain inhibitory
factors. Mycoplasma was assayed using culture (indirect) and indicator cell
culture (direct) methods, while spiroplasma was tested for using both agar
and broth media.
Viral contamination was tested for in vitro by introduction of the test
sample to different cell lines that allow for the detection of a wide range of
human and animal viruses. Inoculated indicator cells (MRC5, Vero and C6/
36) were observed for 28 days for morphological changes attributed to the
growth of viral agents. The inoculated cells were passaged if required to
assess for cytopathic effect (CPE). As some of the potential viral
contaminants may not cause any morphological changes to the cells,
the ability of inoculated cells to adsorb guinea pig erythrocytes to the cell
surface (haemadsorption) was also assessed. For in vivo testing, adult mice,
suckling mice, and guinea pigs were inoculated with test samples to look
for extraneous agents. Embryonated eggs were not tested. For abnormal
toxicity, the test sample was injected into ﬁve healthy mice and two
healthy guinea pigs at the maximum proposed human dose. The animals
were then monitored for ill health or death.
Bacterial endotoxin was assayed in test samples using the chromogenic
kinetic method. Known amounts of endotoxin were tested in parallel with
the test sample for an accurate determination of the level of bacterial
endotoxin. The potential for interference by the test sample was examined
by spiking in speciﬁed levels of endotoxin. Protein concentration was
measured by absorbance at 280 nm (referenced at 320 nm) using a value
for the extinction coefﬁcient of 0.881 (0.1%). For appearance, the ﬁnished
product was visually inspected using a liquid viewer with white and black
backgrounds for the presence/absence of particles. The color of the vialled
product was also assessed using color reference standards. pH was
measured at 25.0 ± 1.0 °C after calibration of the pH meter with
commercially available solutions in the appropriate pH range. Osmolality
was measured after calibration of the osmometer using a 290mOSm/kg
standard. Each test sample was injected in triplicate and the mean value
reported.
For residual host-cell DNA, the sample was extracted and then tested in
a real-time PCR reaction containing target speciﬁc primers and a probe,
alongside a range of positive controls of known host-cell DNA concentra-
tion. For residual host-cell protein analysis, the test sample and positive
comparator sample (S2 cell supernatant) were separated by SDS-PAGE
under reducing conditions followed by western blotting using an anti-S2
cell rat polyclonal antibody (ExpreS2ion Biotechnologies). Residual C-tag
ligand was quantiﬁed using a commercially available CaptureSelect™ C-Tag
Ligand Leakage ELISA Kit (Thermo Fisher Scientiﬁc). For analysis of the
copia retrotransposon, a positive control sample of copia VLP was
prepared by ExpreS2ion Biotechnologies from S2 cell nuclear material
isolated by sucrose density centrifugation followed by hypotonic shock to
release the VLP. This positive control sample and the test sample were
then compared by SDS-PAGE under reducing conditions followed by
western blotting using an anti-copia gag protein rabbit polyclonal
antibody (raised against a synthetic peptide (CRILNNKNKENEKQVQ-
TATSHG) from the C-terminus of the copia capsid protein). The antisera
recognize a protein of ~31 kDa. RH5.1 identity was also conﬁrmed by
western blotting of the test sample following SDS-PAGE under reducing
conditions and detection with the anti-PfRH5 4BA7 mouse monoclonal
antibody (mAb).37 For purity analysis, test samples were separated in the
same manner by SDS-PAGE and then visualized using a Coomassie visible
stain. Bands were observed by densitometry and analyzed to determine
purity.
High-performance liquid chromatography-SEC
To assess for aggregation, test samples were separated isocratically using a
Superdex 200 Increase 3.2/300 SEC column (GE Healthcare, UK) on an
Agilent HPLC 1260 system using a ﬂow rate of 0.075mL/min. The
molecular weight of any peak(s) detected was calculated by calibration
against globular protein markers.
Surface plasmon resonance
The production of recombinant basigin in Origami B (DE3) E. coli has been
previously described.68 A section of the basigin gene encoding immu-
noglobin domains 1 and 2 of the short isoform (aa 22–205) was cloned
with an N-terminal hexa-histidine (His6) tag followed by a tobacco etch
virus (TEV) protease cleavage site. TEV cleavage leaves an additional
glycine at the N-terminus from the cleavage site. Surface plasmon
resonance (SPR) experiments were carried out using a BIAcore T200
instrument (GE Healthcare, UK). Experiments were performed at 20 °C in
10mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% Tween-20, 2 mg/
mL dextran, and 1mg/mL salmon sperm DNA. Basigin was immobilized on
a CM5 chip (GE Healthcare, UK) by amine coupling (GE Healthcare kit, UK)
to a total of 950 Response Units (RU). A concentration series of RH5.1
protein (a two-fold dilution series from 2 μM) was injected over the
basigin-coated chip for 120 s at 30 μL/min, followed by a 300 s dissociation
time. The chip surface was then regenerated with 30 s of 2 M NaCl. Speciﬁc
binding of RH5.1 protein was obtained by subtracting the response from a
blank surface from that of the basigin-coated surface. The kinetic
sensorgrams were ﬁtted to a global 1:1 interaction model, allowing
determination of the dissociation constant, KD, using BIAevaluation
software 1.0 (GE Healthcare, UK).
Potency and mAb ELISAs
RH5.1 protein was coated at 2 μg/mL with 50 μL per well onto a Maxisorp
plate (Thermo Fisher Scientiﬁc, UK) and incubated at 4 °C overnight. The
following day, the plates were washed six times with PBS/0.05% Tween-20
(PBS/T), before blocking with 200 μL per well 5% milk powder (Marvel) in
PBS at room temperature (RT) for 1 h. After washing again six times in PBS/
T, test mAbs were loaded (50 μL in triplicate) onto the plate at 5 μg/mL and
incubated at RT for 2 h. The generation of eight PfRH5-speciﬁc mouse
mAbs has been previously described.37 The positive control included
mouse anti-PfRH5 polyclonal serum diluted 1:1000, and an irrelevant
negative control mouse mAb. After a further 6 times wash, plates were
incubated with goat anti-mouse IgG-alkaline phosphatase (Sigma-Aldrich,
UK) diluted 1:1000 in 5% milk powder/PBS, using 50 μL per well at RT for
1 h. After a ﬁnal six washes in PBS/T, plates were developed by addition of
p-nitrophenyl phosphate substrate diluted in diethanolamine buffer
(Thermo Fisher Scientiﬁc, UK). The optical density at 405 nm (OD405) was
read using an Inﬁnite F50 microplate reader (Tecan, Switzerland) and
Magellan v7.0 software.
Potency of RH5.1 protein was assessed using a sandwich ELISA.
Microplates were coated with the non-neutralizing murine mAb 4BA7 in
PBS. After 6× washing in PBS/T, 200 μL per well Casein Blocker were added
for 1 h at RT. Following another wash, RH5.1 protein standards (100, 50,
and 20% concentration of the engineering batch) and test samples were
added to the plate in a dilution series in triplicate for 1 h at RT. Following
another wash, captured RH5.1 protein was detected for 1 h at RT using the
chimeric human IgG1 mAb 2AC7 which recognizes a conformational
epitope and is known to be highly neutralizing in the assay of GIA.37 Bound
antibody was ﬁnally detected using anti-human IgG-alkaline phosphatase
(Sigma-Aldrich, UK) and developed as above for the mAb ELISA. The
relative potency of the test sample against the standards was then
calculated using a four-parameter non-linear logistic regression model with
calculated EC50 values. OD405 was read using an Inﬁnite F50 microplate
reader (Tecan, Switzerland) and Magellan v7.0 software.
Stability testing of the engineering batch
For SDS-PAGE, protein test samples were heated to 95 °C for 10min in
Laemmli sample buffer containing 50mM dithiothreitol (DTT). Electro-
phoresis was performed on a Criterion Any kD TGX gel (Bio-Rad
Laboratories, UK) at 200 V for 45min. The gels were then stained with
Quick Coomassie Stain (Generon, UK) prior to imaging. For analytical SEC,
test samples were separated isocratically on a Superdex 200 Increase 10/
300 GL column (GE Healthcare, UK) using an ÄKTA Pure 25 system (GE
Healthcare, UK) and in 20mM Tris-HCl, 150 mM NaCl, pH 7.4 (TBS). For dot
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blots, RH5.1 protein was spotted in a dilution series onto nitrocellulose
membrane (Bio-Rad Laboratories, UK) and air-dried. Afterwards, the
membrane was processed in an iBind device (Thermo Fisher Scientiﬁc,
UK), containing 2AC7 mouse mAb as primary at 1 μg/mL followed by an
alkaline phosphatase-conjugated anti-mouse IgG secondary diluted
1:1000. Finally, the dot blot was developed with Sigmafast BCIP/NBT
alkaline phosphatase substrate (Sigma-Aldrich, UK) prior to imaging.
AS01B formulation study
To characterize the RH5.1/AS01B vaccine formulation, protein vaccine was
thawed and added to vials of Adjuvant System AS01B (provided by GSK) as
per the clinical SOP. Samples were removed at deﬁned time points (0, 1,
and 4 h post mixing), heated to 95 °C for 10min in reducing sample buffer
and stored at −20 °C. SDS-PAGE was performed as for the stability testing.
Dynamic light scattering
RH5.1 protein vaccine was mixed with AS01B adjuvant to a ﬁnal
concentration of 63 μg/mL. DLS measurements were performed with at
least 2 technical replicates of 11 measurements each running for >10 s for
Z-average diameter. Malvern Instrument’s Zetasizer Nano and zeta cells
(DTS1070) were used for the measurement, with parameters that were
estimated to be closest to the actual formulation of AS01B (dispersant PBS,
refractive index 1.330, viscosity 0.8872cP). Brieﬂy, the method detects and
analyzes ﬂuctuations in the intensity of light scattered by the particles
when irradiated with red light (HeNe laser, wavelength λ 632.8 nm). Such
ﬂuctuations are detected at a backscattering angle of 173° and analyzed to
obtain autocorrelation function using Malvern’s Zetasizer software version
7.11. The Z-average and polydispersity index values are provided from the
cumulant analysis of the autocorrelation function by the software.
Mice and immunizations
RH5.1 protein (either cGMP batch or engineering batch) was thawed for
15min at RT before removal from vials using a syringe ﬁtted with a 5 μm
ﬁlter (Helapet IV1520 ﬁlter needle). This needle was then exchanged with a
non-ﬁltered 23 G needle and the protein transferred into another tube for
dilution. Proteins were diluted in sterile PBS before mixing gently 1:1 with
AS01B adjuvant. The formulated vaccine was administered to mice within
1 h of mixing. All procedures on mice were performed in accordance with
the terms of the UK Animals (Scientiﬁc Procedures) Act Project Licence and
were approved by the University of Oxford Animal Welfare and Ethical
Review Body. Female BALB/c (H-2d) mice aged 6–8 weeks were purchased
from Harlan Laboratories (Oxfordshire, UK). Mice were anaesthetized with
Isoﬂo (Abbot Animal Health, UK), and then immunized intramuscularly (i.
m.) with 2 μg RH5.1 vaccine (50 μL in total) divided equally into each
medial hamstring. Mice received three identical immunizations at 4-week
intervals. Serum was harvested at stated time points from tail vein bleeds
or by exsanguination under terminal anesthesia at the ﬁnal harvest time
point (2 weeks post-ﬁnal boost).
Ex vivo IFN-γ spleen enzyme-linked immunospot assay
Interferon-gamma (IFN-γ) ELISpot assays were performed using spleno-
cytes as previously described.10 In brief, spleen cells were re-suspended at
1 × 107 cells per mL in complete medium and plated at 50 μL cells per well.
A 50 μL complete medium alone was added to control wells, and 50 μL re-
stimulation in complete medium was added to duplicate test wells as
follows: recombinant RH5.1 protein at a ﬁnal concentration 5 μg/mL; or a
pool of three peptides containing known H-2d T-cell epitopes within PfRH5
(A7= TYDKVKSKCNDIKNDLIATI [10 μg/mL]; C9= NLNKKMGSYIYIDTIKFIHK
[1 μg/mL]; and D9= YIDTIKFIHKEMKHIFNRIE [1 μg/mL]) (NeoBiolab, USA).
Results are expressed as spot forming units (SFU) per million splenocytes.
Background responses in media-only wells were subtracted from those
measured in re-stimulated wells.
Anti-RH5.1 IgG enzyme-linked immunosorbent assay
Mouse anti-RH5.1 serum IgG responses were measured using a standar-
dized ELISA according to previously described methodology72,73 and using
a reference sample generated from high-titer sera pooled from PfRH5
vaccinated mice. A 1:8000 dilution of the reference sample gave an OD405
= 1.0, and thus this reference serum was taken to be 8000 arbitrary units
(AU). Test samples were diluted appropriately so that their OD405 could be
read off the linear part of the reference curve.
Assay of growth inhibition activity against P. falciparum
Total IgG was puriﬁed from mouse sera using protein G columns (Pierce)
and subsequently RBC depleted. The P. falciparum 3D7 clone laboratory-
adapted line was maintained in continuous culture using fresh O+
erythrocytes at 2% hematocrit and synchronized by two incubations in 5%
sorbitol 6–8 h apart. Synchronized trophozoites were adjusted to 0.4%
parasitemia and then incubated for 44 h with the various IgG concentra-
tions at 1% hematocrit. Final parasitemia was quantiﬁed by thin blood ﬁlm
of a tracker culture grown in parallel and growth inhibition was assessed
by biochemical determination of parasite lactate dehydrogenase.40
Percentage growth inhibition is expressed relative to wells containing
culture medium only (infection control, 0% growth inhibition) after
subtraction of background signal (5 mM EDTA, uninfected control). The
mean of the three replicate wells was taken to obtain the ﬁnal data for
each pooled mouse group at each tested IgG concentration. Experiments
were performed twice with very similar results.
Statistical analysis
Data were analyzed using GraphPad Prism version 6.07 for Windows
(GraphPad Software Inc., California, USA). For the non-linear least squares
regression, the equation: Y= bottom+ (top−bottom)/(1+ 10
((logEC50−X) × HillSlope)) was used with four-parameter curve and log10-
transformed ELISA data, constrained at the top to <100% and at the
bottom to >0% GIA. In the immunized mice, responses between the two
test proteins were assessed by two-tailed Mann–Whitney test (as opposed
to versus the negative control group) as the primary experimental question
was to assess their comparability.
Data and materials availability
Requests for data or materials should be addressed to the corresponding
author.
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